½ÃÀ庸°í¼­
»óǰÄÚµå
1623381

¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå ±Ô¸ð : À¯Çüº°, ¿ä¹ýº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°, ¹üÀ§ ¹× ¿¹Ãø

Global Wearable Injector Devices Market Size By Type (On-Body Injectors, Off-Body Injectors), By Therapy (Immuno-Oncology, Diabetes), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Verified Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 202 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø

¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 86¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2031³â¿¡´Â 187¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024-2031³âÀÇ CAGRÀº 10.21%·Î ¼ºÀåÇÕ´Ï´Ù. ¿þ¾î·¯ºí ÀÎÁ§ÅÍ´Â ±âÁ¸ÀÇ ÈÞ´ë¿ë ÈÞ´ë¿ë Àåºñ¸¦ »ç¿ëÇÏ¿© ¾à¹°À» Åõ¿©ÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ȯÀÚ°¡ Á¤±âÀûÀ¸·Î ¾àÀ» º¹¿ëÇÏ´Â µ¥ »ç¿ëÇÏ´Â ÀÚü È®Àå °¡´ÉÇÑ ÀÚ°¡ Åõ¿© ½Ã½ºÅÛÀÔ´Ï´Ù. ´ç´¢º´, ºñ¸¸, °íÇ÷¾Ð µî ¸¸¼ºÁúȯÀ» ¾Î°í ÀÖ´Â »ç¶÷µé¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ¿þ¾î·¯ºí ÀÎÁ§ÅÍ´Â ¸é¹ÐÇÑ ¸ð´ÏÅ͸µ ÇÏ¿¡ ÀÇ·á¿ë ¾×üÀÇ Á¤È®ÇÑ Àü´ÞÀ» °³¼±ÇÕ´Ï´Ù. º´¿ø, ÀçÅà ¿ä¾ç ½Ã¼³, Áø·á¼Ò µî¿¡¼­ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ¾Ï°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, Áúº´ Ä¡·á¸¦ À§ÇÑ ´ÜŬ·Ð Ç×ü¿Í °°Àº »ý¹°Á¦Á¦ÀÇ »ç¿ë Áõ°¡, ½º¸¶Æ®Æù°úÀÇ ºí·çÅõ½º ¿¬°á ¹× µðÁöÅÐ µð½ºÇ÷¹ÀÌ¿Í °°Àº ±â´ÉÀ» °®Ãá ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ¿¬±¸ ¹× °³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁö°í ÀÖ½À´Ï´Ù. °³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁö¸é¼­ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

³ë³âÃþ ȯÀÚ Áõ°¡¿Í ÀçÅÃÄ¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ½ÃÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àß ±¸ÃàµÈ ÀÇ·á ÀÎÇÁ¶óÀÇ Á¸Àç¿Í »ýȰ½À°üº´ÀÇ ºóµµ Áõ°¡µµ ½ÃÀå È®´ëÀÇ µÎ °¡Áö ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀåÀº ½ÅÈï ±¹°¡ ½ÃÀåÀÇ ³·Àº ¼ö¿ä¿Í ¿þ¾î·¯ºí ÀÎÁ§ÅÍ¿Í °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ½ÃÀåÀÌ ¾ïÁ¦µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿þ¾î·¯ºí ÀÎÁ§ÅÍ´Â ÇコÄɾî ÀÎÇÁ¶ó¿Í Ä¿³ØÆ¼µå Çコ ¼­ºñ½ºÀÇ Å« °ÝÂ÷¸¦ ÇØ¼ÒÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ¸¸¼º ÆóÁúȯ, ½ÉÇ÷°üÁúȯ, ½Å°æÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀÌ COVID-19ÀÇ Àå±âÀûÀÎ ¿µÇâÀ» °ü¸®Çϱ⠽ÃÀÛÇÔ¿¡ µû¶ó COVID-19 °¨¿°À¸·Î ÀÎÇÑ ¸¸¼ºÁúȯ Áõ°¡´Â ¿þ¾î·¯ºí ÀÎÁ§ÅÍ µµÀÔÀÇ ¿øµ¿·ÂÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀº COVID-19¿¡ ³ëÃâµÇ´Â °ÍÀ» ÇÇÇϱâ À§ÇØ Áø·á¼Ò¿¡¼­ Áý¿¡¼­ ¾à¹°À» Åõ¿©ÇÏ´Â ¹æ½ÄÀ¸·Î ÀüȯÀ» ¿øÇϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå ¿ªÇÐ

¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ½ÃÀå ¿ªÇÐ

ÁÖ¿ä ½ÃÀå Ȱ¼ºÈ­ ¿äÀÎ

¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡

´ç´¢º´, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ ºó¹øÇϰí Á¤È®ÇÑ ¾à¹°Àü´ÞÀÌ ÇÊ¿äÇϸç, ÀÌ¿¡ µû¶ó °£ÆíÇϰí È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÏ´Â ¿þ¾î·¯ºí ÀÎÁ§ÅÍ µð¹ÙÀ̽º°¡ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

±â¼úÀÇ ¹ßÀü

¼ÒÀç °³¼±, ¼ÒÇüÈ­, ¹«¼±Åë½Å µî ¿þ¾î·¯ºí ±â¼úÀÇ ±â¼ú ¹ßÀüÀº ¿þ¾î·¯ºí ÀÎÁ§ÅÍÀÇ ±â´É¼º°ú »ç¿ë ÆíÀǼºÀ» Çâ»ó½ÃÄÑ È¯ÀÚ¿Í ÀÇ·á Àü¹®°¡¿¡°Ô ´õ¿í ¸Å·ÂÀûÀ¸·Î ´Ù°¡°¥ ¼ö ÀÖ°Ô Çß½À´Ï´Ù.

ȨÄɾ ´ëÇÑ È¯ÀÚ ¼±È£µµ:

º´¿ø ¹æ¹® Ƚ¼ö¿Í ÀÇ·áºñ Àý°¨¿¡ ´ëÇÑ ¿­¸Á¿¡ ÈûÀÔ¾î ¾à¹° ÀÚ°¡ Åõ¿© ¹× ÀçÅà ġ·áÀÇ Ãß¼¼°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿þ¾î·¯ºí ÀÎÁ§Åʹ ȯÀÚ°¡ µ¶¸³ÀûÀ¸·Î Ä¡·á¸¦ °ü¸®ÇÒ ¼ö ÀÖ´Â È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù.

ÁöÁöÀûÀÎ ±ÔÁ¦ Á¤Ã¥:

FDA ¹× EMA¿Í °°Àº º¸°Ç ´ç±¹ÀÇ À¯¸®ÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í ¿þ¾î·¯ºí ÀÎÁ§ÅÍ¿¡ ´ëÇÑ ½ÂÀÎ Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥Àº ¿þ¾î·¯ºí ÀÎÁ§ÅÍÀÇ ¾ÈÀü¼º, À¯È¿¼º ¹× ǰÁúÀ» º¸ÀåÇϰí ÀÓ»ó ÇöÀå¿¡¼­ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä °úÁ¦

±ÔÁ¦ Àå¾Ö¹° ¹× ±ÔÁ¤ Áؼö:

º¹ÀâÇÏ°í ±î´Ù·Î¿î ±ÔÁ¦ »óȲÀ» ±Øº¹ÇÏ´Â °ÍÀº ¿þ¾î·¯ºí ÀÎÁ§ÅÍ¿¡ ÀÖÀ¸¸ç, Å« Àå¾Ö¹°ÀÔ´Ï´Ù. Á¦Á¶¾÷ü´Â Á¦Ç°ÀÌ FDA ¹× EMA¸¦ Æ÷ÇÔÇÑ ¿©·¯ ¼¼°è º¸°Ç ±â°üÀÇ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·ÇÏ´ÂÁö È®ÀÎÇØ¾ß ÇÕ´Ï´Ù. À̸¦ À§Çؼ­´Â ¾ÈÀü¼º°ú À¯È¿¼ºÀ» ÀÔÁõÇϱâ À§ÇÑ ±¤¹üÀ§ÇÑ Å×½ºÆ®¿Í ¹®¼­È­°¡ ÇÊ¿äÇϸç, ÀÌ´Â ½Ã°£°ú ºñ¿ëÀÌ ¸¹ÀÌ ¼Ò¿äµË´Ï´Ù. ±ÔÁ¤ Áؼö À§¹ÝÀº Á¦Ç° ½ÂÀÎ ¹× ½ÃÀå ÁøÀÔÀ» Áö¿¬½ÃÄÑ ¸ÅÃâ°ú ½ÃÀå °æÀï¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

±â¼úÀû, µðÀÚÀÎÀû °úÁ¦:

»ç¿ëÇϱ⠽±°í, ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç, ´Ù¾çÇÑ ¾à¹°À» Á¤È®ÇÏ°Ô Àü´ÞÇÒ ¼ö ÀÖ´Â ¿þ¾î·¯ºí ÀÎÁ§Å͸¦ ¸¸µå´Â °ÍÀº ±â¼úÀûÀ¸·Î Å« Àå¾Ö¹°ÀÌ ÀÖ½À´Ï´Ù. ÀÛ°í °¡º±°í Æí¾ÈÇÑ ±â±â¸¦ À¯ÁöÇϸ鼭 ¿¬°á ¹× ÀÚµ¿ ¾à¹°Àü´Þ°ú °°Àº °í±Þ ±â´ÉÀ» °áÇÕÇÏ·Á¸é Àü¹®ÀûÀÎ ¿£Áö´Ï¾î¸µÀÌ ÇÊ¿äÇÕ´Ï´Ù. ´Ù¾çÇÑ ±â»ó Á¶°Ç°ú »ç¿ë ½Ã³ª¸®¿À¿¡¼­ ±â±âÀÇ ¼º´ÉÀ» À¯ÁöÇÏ´Â °ÍÀº ¹®Á¦¸¦ ´õ¿í º¹ÀâÇÏ°Ô ¸¸µì´Ï´Ù.

½ÃÀå ¼ö¿ë ¹× äÅà :

ÀÇ·áÁø°ú ȯÀÚÀÇ ¼ö¿ë°ú äÅÃÀº ¸Å¿ì Áß¿äÇÏÁö¸¸ ¾î·Á¿î ÀÏÀÔ´Ï´Ù. »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ ³¸¼³À½°ú ¾ÈÀü¼º ¹× È¿°ú¿¡ ´ëÇÑ ¿ì·Á´Â Á¾Á¾ ÀúÇ×ÀÇ ¿øÀÎÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ À庮À» ±Øº¹Çϱâ À§Çؼ­´Â ÀÌÇØ°ü°èÀÚ¸¦ ±³À°Çϰí, ÀÌÁ¡À» º¸¿©ÁÖ°í, ±â±â°¡ ±âÁ¸ ÀÇ·á °üÇà¿¡ ½±°Ô ÅëÇÕµÉ ¼ö ÀÖµµ·Ï ÇØ¾ß ÇÕ´Ï´Ù. ȯÀÚÀÇ ¼øÀÀµµµµ Áß¿äÇϹǷΠÁ÷°üÀûÀÌ°í ¹æÇذ¡ µÇÁö ¾Ê´Â µðÀÚÀÎÀ̾î¾ß ÇÕ´Ï´Ù.

ºñ¿ë°ú »óȯÀÇ ¹®Á¦:

¿þ¾î·¯ºí ÀÎÁ§ÅÍ´Â °³¹ß ¹× Á¦Á¶ ºñ¿ëÀÌ ³ô±â ¶§¹®¿¡ °¡°Ý Ã¥Á¤ ¹× ½ÃÀå ħÅõ¿¡ ¾î·Á¿òÀÌ ÀÖ½À´Ï´Ù. º¸Çè»ç·ÎºÎÅÍÀÇ »óȯÀ» ¹Þ´Â °ÍÀº ´õ ¸¹Àº º¸±ÞÀ» À§ÇØ Áß¿äÇÏÁö¸¸, ºñ¿ë È¿À²¼º°ú ÀÓ»óÀû ¿ì¿ù¼ºÀ» º¸¿©ÁÖ´Â °­·ÂÇÑ Áõ°Å°¡ ¾øÀ¸¸é ¾î·Æ½À´Ï´Ù. Á¦Á¶¾÷ü´Â º¸Çè ÁöºÒÀÚ¿Í Çù·ÂÇÏ¿© À¯¸®ÇÑ »óȯ °æ·Î¸¦ ±¸ÃàÇØ¾ß Çϴµ¥, ¿©±â¿¡´Â ºñ¿ëÀÌ ¸¹ÀÌ µå´Â ÀÓ»ó ¿¬±¸ ¹× ÀÇ·á °æÁ¦¼º Á¶»ç°¡ Æ÷Ç﵃ ¼ö ÀÖ½À´Ï´Ù.

ÁÖ¿ä µ¿Çâ :

±â¼úÀÇ Áøº¸¿Í Çõ½Å :

¿þ¾î·¯ºí ÀÎÁ§ÅÍ¿¡ ½º¸¶Æ® ±â´ÉÀÌ Å¾ÀçµÇ´Â µî ±â¼ú ¹ßÀüÀ¸·Î ½ÃÀåÀÌ ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´É¿¡´Â ºí·çÅõ½º ¿¬°á, ½Ç½Ã°£ ¸ð´ÏÅ͸µ, ¾Û ÅëÇÕ µîÀÌ Æ÷ÇԵǸç, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿¡°Ô À¯¿ëÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÕ´Ï´Ù.

¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡:

´ç´¢º´, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¿þ¾î·¯ºí ÀÎÁ§ÅÍ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â Àå±âÀûÀΠó¹æ ¿ä¹ýÀ» °ü¸®ÇÒ ¼ö ÀÖ´Â ½Ç¿ëÀûÀ̰í È¿°úÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇϰí, Áý¿¡¼­ Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù.

ȯÀÚ Áß½ÉÀÇ ÇコÄÉ¾î ¼Ö·ç¼Ç :

ȯÀÚ Á᫐ ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ µµÀÔÀÌ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â »ç¿ëÇϱ⠽±µµ·Ï ¼³°èµÇ¾î ºÒÆíÇÔÀ» ÁÙÀ̰í ÀÚ°¡ Áֻ縦 ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ¿òÁ÷ÀÓÀº »ç¶÷µéÀÌ ÀÚ½ÅÀÇ Ä¡·á¸¦ ½º½º·Î °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ¸ÂÃãÇü ÀÇ·áÀÇ Ãß¼¼¸¦ ÃËÁøÇÕ´Ï´Ù.

±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ¹× ½ÃÀå È®´ë:

¿þ¾î·¯ºí ÀÎÁ§ÅͰ¡ Àü ¼¼°è¿¡¼­ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹ÞÀ¸¸é¼­ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ´Â °¡¿ë¼ºÀ» È®´ëÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¾ÈÀü¼º°ú È¿°ú¿¡ ´ëÇÑ °í°´ÀÇ ½Å·Ú¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â¾÷Àº Àü·«Àû Á¦ÈÞ¿Í Çù¾÷À» ÅëÇØ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϰí ÀÖÀ¸¸ç, À̸¦ ÅëÇØ Á¦Ç° µµ´Þ ¹üÀ§¿Í äÅ÷üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : ¼­·Ð

  • ½ÃÀåÀÇ ¼­·Ð
  • Á¶»ç ¹üÀ§
  • ÀüÁ¦Á¶°Ç

Á¦2Àå °³¿ä

Á¦3Àå VERIFIED MARKET RESEARCHÀÇ Á¶»ç ¹æ¹ý

  • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • ¹ë¸®µ¥À̼Ç
  • ÀÏÂ÷ ÀÚ·á
  • µ¥ÀÌÅÍ ¼Ò½º ¸®½ºÆ®

Á¦4Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå Àü¸Á

  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ÃËÁø¿äÀÎ
  • ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • Porter's Five Forces ¸ðµ¨
  • ¹ë·ùüÀÎ ºÐ¼®

Á¦5Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : À¯Çüº°

  • °³¿ä
  • ¿Â º¸µð ÀÎÁ§ÅÍ
  • ¿ÀÇÁ º¸µð ÀÎÁ§ÅÍ

Á¦6Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : ¿ä¹ýº°

  • °³¿ä
  • ¸é¿ª Á¾¾çÇÐ
  • ´ç´¢º´
  • ½ÉÇ÷°üÁúȯ

Á¦7Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • °³¿ä
  • º´¿ø
  • ÀçÅà ÀÇ·á
  • Áø·á¼Ò

Á¦8Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ÇÁ¶û½º
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • ÀϺ»
  • Àεµ
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼¼°èÀÇ ±âŸ Áö¿ª
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ¼¼°èÀÇ ¿þ¾î·¯ºí ÀÎÁ§ÅÍ ½ÃÀå : °æÀï ±¸µµ

  • °³¿ä
  • °¢»ç ½ÃÀå ¼øÀ§
  • ÁÖ¿ä °³¹ß Àü·«

Á¦10Àå ±â¾÷ °³¿ä

  • Valeritas
  • SteadyMed Therapeutics
  • Tandem Diabetes Care
  • Amgen
  • Medtronic
  • Insulet Corporation
  • United Therapeutic Corporation
  • Enable Injections
  • Ypsomed and Becton
  • Dickinson and Company

Á¦11Àå ºÎ·Ï

  • °ü·Ã Á¶»ç
KSA 25.01.17

Wearable Injector Devices Market Size And Forecast

Wearable Injector Devices Market size was valued at USD 8.62 Billion in 2023 and is projected to reach USD 18.77 Billion by 2031 , growing at a CAGR of 10.21% from 2024 to 2031. Wearable injectors are used to give drugs through a conventional handheld portable device. It is a self-scalable, self-administration system that patients use to take their medication on a regular basis. It is essential for people suffering from chronic conditions like diabetes, obesity, and hypertension. The wearable injector improves the accurate delivery of medical fluid under careful supervision. It is widely used in hospitals, home care facilities, clinics, and other settings. The market is growing due to the rising prevalence of chronic diseases such as diabetes, cardiovascular disease, and cancer, as well as the increased use of biologics such as monoclonal antibodies for disease treatment and increased R&D activities in wearable injector devices with features such as Bluetooth connectivity with a smartphone and a digital display.

The growing number of geriatric patients and demand for home-based therapy are moving the market ahead. Furthermore, the presence of well-established healthcare infrastructure, as well as an increase in the frequency of lifestyle-related disorders, are two other factors driving market expansion. However, the Wearable Injector Devices Market is projected to be restrained by low demand in developing nations and the high costs associated with wearable injectors.

Wearable injectors are expected to solve significant gaps in healthcare infrastructure and connected health services. As patients with chronic pulmonary, cardiovascular, and neurological problems begin to manage the long-term consequences of the condition, an increase in chronic ailments caused by COVID-19 morbidity may help drive development in the adoption of wearable injectors. Patients with chronic conditions are asking a switch from clinic to at-home drug administration to avoid COVID-19 exposure.

Global Wearable Injector Devices Market Dynamics

The key market dynamics that are shaping the global Wearable Injector Devices Market include:

Key Market Drivers:

Rising Prevalence of Chronic Diseases

: The rising prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders needs frequent and precise drug delivery, resulting in a desire for wearable injector devices that provide simple and effective treatment choices.

Technological Advancements

: Technological advancements in wearable technology, including as improved materials, downsizing, and wireless communication, improve the functionality and usability of wearable injectors, making them more appealing to patients and healthcare professionals.

Patient Preference for Home-Based Care:

There is a growing trend towards self-administration of medications and home-based care, fueled by the desire to reduce hospital visits and healthcare costs. Wearable injectors provide an efficient solution for patients to manage their treatment independently.

Supportive Regulatory Policies:

Favorable regulatory frameworks and increased approvals of wearable injector devices by health authorities like the FDA and EMA facilitate market growth. These policies ensure the safety, efficacy, and quality of wearable injectors, boosting their adoption in clinical practice.

Key Challenges:

Regulatory Hurdles and Compliance:

Navigating the complicated and strict regulatory landscape is a significant hurdle for wearable injector devices. Manufacturers must guarantee that their products meet the regulatory standards of several worldwide health bodies, including the FDA and EMA. This entails extensive testing and documentation to prove safety and efficacy, which can be time-consuming and expensive. Non-compliance can cause delays in product approval and market access, affecting revenue and competitiveness.

Technological and Design Challenges:

Creating wearable injector devices that are user-friendly, dependable, and capable of precisely delivering a wide range of drugs has substantial technical obstacles. Keeping the gadgets small, lightweight, and comfy while combining advanced capabilities like connection and automated drug delivery necessitates expert engineering. Maintaining device performance under a variety of weather settings and usage scenarios further complicates matters.

Market Acceptance and Adoption:

Gaining acceptance and adoption from healthcare professionals and patients is crucial but difficult. Unfamiliarity with new technologies, as well as concerns about safety and efficacy, frequently cause resistance. Overcoming these barriers requires educating stakeholders, demonstrating advantages, and ensuring that the devices integrate easily into existing healthcare practices. Patient adherence is also critical, thus designs must be intuitive and least obtrusive.

Cost and Reimbursement Issues:

Wearable injector devices can be costly to develop and manufacture, offering pricing and market penetration challenges. Receiving reimbursement from insurance companies is critical for wider adoption, but this can be difficult without strong evidence of cost-effectiveness and clinical advantages. Manufacturers must collaborate with payers to build advantageous reimbursement routes, which can include costly clinical studies and health economic studies.

Key Trends:

Technological Advances and Innovations:

The market is expanding rapidly as a result of technological advances such as the incorporation of smart features into wearable injectors. These features include Bluetooth connectivity, real-time monitoring, and app integration, which improve patient compliance and give useful data to healthcare providers.

Increasing Prevalence of Chronic Diseases:

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders is fueling demand for wearable injectors. These devices provide a practical and effective approach to managing long-term prescription regimens, enhancing patient quality of life by allowing for at-home care.

Patient-Centered Healthcare Solutions:

The rising emphasis on patient-centered healthcare is driving the introduction of wearable injectors. These devices are designed to be user-friendly, reducing discomfort and allowing for self-administration. This move advances the trend of individualized medicine by empowering people to manage their own care.

Regulatory Approvals and Market Expansion:

The market is developing as more wearable injectors obtain regulatory authorization around the world. This not only expands their availability but also raises customer trust in their safety and efficacy. Furthermore, organizations are increasing their market presence through strategic alliances and collaborations, which improve product reach and adoption.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Wearable Injector Devices Market Regional Analysis

Here is a more detailed regional analysis of the global Wearable Injector Devices Market:

North America:

North America has a well-developed healthcare infrastructure that facilitates the introduction of innovative medical technologies, such as wearable injector devices. The existence of world-class hospitals, research institutions, and healthcare facilities enables the rapid integration of these devices into patient care. Furthermore, the region has strong healthcare funding and reimbursement rules that promote innovation and use of cutting-edge medical technologies.

The increased prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disease in North America fuels demand for wearable injector devices. These devices provide a simple and effective way to manage long-term pharmaceutical regimens, which is critical for patients with chronic diseases. The growing number of patients requiring ongoing therapy creates a significant market for these advanced drug delivery systems.

North America's strong regulatory environment protects the safety and efficacy of medical products, boosting consumer confidence. Regulatory bodies such as the FDA establish clear guidelines and pathways for the approval and commercialization of wearable injectors. This regulatory support not only speeds up the introduction of innovative technologies to the market, but it also reassures healthcare providers and patients about their dependability.

The region is a hotbed of technical innovation and healthcare-related research and development. Companies and research organizations in North America are investing extensively in next-generation wearable injectors with advanced features including connectivity and real-time monitoring. This ongoing focus on innovation improves product offerings and establishes North America as a market leader in wearable injector devices.

Asia Pacific:

Asia Pacific is experiencing significant expansion in healthcare infrastructure, which is fueling the growth of the Wearable Injector Devices Market. Governments throughout the area are raising healthcare budgets and investing in cutting-edge medical technologies to improve patient care. This investment promotes the use of novel equipment such as wearable injectors in hospitals and clinics. Improved healthcare facilities attract a larger patient population, which fuels market expansion.

Diabetes, cancer, and cardiovascular disease are all on the rise in the region. This surge in chronic illnesses needs long-term and efficient treatment alternatives, making wearable injectors an intriguing solution. These technologies enable patients to manage their diseases at home, minimizing the need for frequent hospital visits. The expanding patient population, with chronic diseases boosts the demand for wearable injectors.

Economic expansion in countries such as China, India, and Japan is resulting in increasing disposable incomes and healthcare spending among the population. People with larger financial means are more inclined to invest in innovative healthcare solutions, such as wearable injector devices. Furthermore, increased healthcare knowledge and education are encouraging people to seek out better and more convenient treatment options, hence promoting market growth.

The regulatory climate in Asia Pacific is becoming more conducive to medical device innovation and commercialization. Governments are creating favorable regulations and expediting the approval process for new medical technologies. This creates a favorable environment for the introduction and use of wearable injector devices. The ease with which regulatory licenses are granted increases market entry and expansion for regional producers and distributors of such devices.

Global Wearable Injector Devices Market: Segmentation Analysis

The Global Wearable Injector Devices Market is Segmented on the basis of Type, Therapy, End-User, And Geography.

Wearable Injector Devices Market, By Type

  • On-Body Injectors
  • Off-Body Injectors

Based on Type, the market is segmented into On-Body Injectors and Off-Body Injectors. On-body wearable injectors accounted for the greatest revenue share in 2023, owing to rising demand because these patches are pleasant to wear on the skin (stomach), are water resistant, and are convenient to use at home. On-body wearable injectors have several advantages, including fewer hospital visits, lower healthcare costs, lifecycle management, customizable dosing, and automatic warming of cold medications. Off-body wear removes hazards such as painful device removal, adhesive fitting difficulties, and skin sensitivity or irritation.

Wearable Injector Devices Market, By Therapy

  • Immuno-Oncology
  • Diabetes
  • Cardiovascular Diseases

Based on Therapy, The market is segmented into Immuno-Oncology, Diabetes, and Cardiovascular Diseases. During the projection period, the diabetes category has the most share. This category's significant position may be attributable to the rising prevalence of diabetes worldwide, as well as the increasing availability of wearable injectors for the treatment of chronic diseases, which is moving this market segment forward.

Wearable Injector Devices Market, By End-User

  • Hospitals
  • Home Care Settings
  • Clinics

Based on End-User, The market is segmented into Hospitals, Home Care Settings, and Clinics. The hospital and clinic segment has a larger market share. The growing preference for self-administration of medication, as well as the growing need to cut healthcare costs, can be attributed to this segment's significant share. Furthermore, the growing need for technologically advanced drug administration systems that lower hospitalization rates while requiring minimal expertise is expected to drive the home healthcare settings market ahead.

Wearable Injector Devices Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on Geography, The Global Wearable Injector Devices Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The Wearable Injector Devices Market in North America is the world's largest. The high prevalence of chronic and lifestyle-related illnesses, as well as the availability of advanced healthcare infrastructure in the region, account for North America's large share of this market.

Key Players

  • The "Global Wearable Injector Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Valeritas, SteadyMed Therapeutics, Tandem Diabetes Care, Amgen, Medtronic, Insulet Corporation, United Therapeutic Corporation, Enable Injections, Ypsomed and Becton, Dickinson and Company.
  • The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

  • Wearable Injector Devices Market Recent Developments
  • In February 2023, Insulet Corporation purchased the assets of Automated Glucose Control LLC (AGC), a firm dedicated to developing and marketing best-in-class automated insulin delivery technology. The company participated in the creation of Omnipod (Insulet's flagship product).
  • In January 2023, Tandem purchased Capillary Biomedical, an infusion set developer.
  • In July 2022, Becton Dickinson and Company purchased Parata Systems. This acquisition will assist BD's market growth.
  • In January 2022, enable injections were obtained. The company obtained USD 215 million in Series C investment. The cash will be used to onboard Enable Injections and major new pharma partner initiatives, as well as to speed the commercialization of their products and platforms with existing pharma partners.
  • In September 2021, Ypsomed AG introduced the YpsoDose single-use injector, which is an electromechanical pre-filled and pre-assembled patch device for 10 mL glass cartridges. Automatically completed steps include needle insertion, injection, end-of-injection feedback, and needle safety. The needle is kept hidden at all times and is rendered safe following injection and device removal.

TABLE OF CONTENTS

1. Introduction of Global Wearable Injector Devices Market

  • Introduction of the Market
  • Scope of Report
  • Assumptions

2. Executive Summary

3. Research Methodology of Verified Market Research

  • Data Mining
  • Validation
  • Primary Interviews
  • List of Data Sources

4. Global Wearable Injector Devices Market Outlook

  • Overview
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Porters Five Force Model
  • Value Chain Analysis

5. Global Wearable Injector Devices Market, By Type

  • Overview
  • On-Body Injectors
  • Off-Body Injectors

6. Global Wearable Injector Devices Market, By Therapy

  • Overview
  • Immuno-Oncology
  • Diabetes
  • Cardiovascular Diseases

7. Global Wearable Injector Devices Market, By End-User

  • Overview
  • Hospitals
  • Home Care Settings
  • Clinics

8. Global Wearable Injector Devices Market, By Geography

  • Overview
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Rest of the World
  • Latin America
  • Middle East & Africa

9. Global Wearable Injector Devices Market Competitive Landscape

  • Overview
  • Company Market Ranking
  • Key Development Strategies

10. Company Profiles

  • Valeritas
  • SteadyMed Therapeutics
  • Tandem Diabetes Care
  • Amgen
  • Medtronic
  • Insulet Corporation
  • United Therapeutic Corporation
  • Enable Injections
  • Ypsomed and Becton
  • Dickinson and Company

11. Appendix

  • Related Research
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦